378 related articles for article (PubMed ID: 26840081)
1. Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
Toyoda H; Wada H; Miyata T; Amano K; Kihira K; Iwamoto S; Hirayama M; Komada Y
J Pediatr Hematol Oncol; 2016 Apr; 38(3):e137-9. PubMed ID: 26840081
[TBL] [Abstract][Full Text] [Related]
2. [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
Okano M; Matsumoto T; Nakamori Y; Ino K; Miyazaki K; Fujieda A; Sugimoto Y; Tawara I; Yamaguchi M; Ohishi K; Miwa H; Masuya M; Wada H; Katayama N
Rinsho Ketsueki; 2018; 59(2):178-181. PubMed ID: 29515070
[TBL] [Abstract][Full Text] [Related]
3. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan.
Matsumoto T; Toyoda H; Amano K; Hirayama M; Ishikawa E; Fujimoto M; Ito M; Ohishi K; Katayama N; Yoshida Y; Matsumoto M; Kawamura N; Ikejiri M; Kawakami K; Miyata T; Wada H
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1301-1307. PubMed ID: 29695177
[TBL] [Abstract][Full Text] [Related]
4. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Vondrák K; Seeman T
Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
6. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
7. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
[TBL] [Abstract][Full Text] [Related]
10. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
Alabdulqader M; Alfakeeh K
BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
[TBL] [Abstract][Full Text] [Related]
11. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
12. Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.
Cullinan N; Gorman KM; Riordan M; Waldron M; Goodship TH; Awan A
Pediatrics; 2015 Jun; 135(6):e1506-9. PubMed ID: 25941307
[TBL] [Abstract][Full Text] [Related]
13. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
14. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
[TBL] [Abstract][Full Text] [Related]
16. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
Kerboua KE; Haiba F; Batouche D
J Immunoassay Immunochem; 2017; 38(2):178-189. PubMed ID: 27617501
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.
Yeter HH; Derici U; Arinsoy T; Altok K; Erten Y; Guz G
Rom J Intern Med; 2022 Mar; 60(1):56-65. PubMed ID: 34449174
[No Abstract] [Full Text] [Related]
19. aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.
Siomou E; Gkoutsias A; Serbis A; Kollios K; Chaliasos N; Frémeaux-Bacchi V
Pediatr Nephrol; 2016 Mar; 31(3):513-7. PubMed ID: 26572892
[TBL] [Abstract][Full Text] [Related]
20. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.
Matsumoto T; Fan X; Ishikawa E; Ito M; Amano K; Toyoda H; Komada Y; Ohishi K; Katayama N; Yoshida Y; Matsumoto M; Fujimura Y; Ikejiri M; Wada H; Miyata T
Int J Hematol; 2014 Nov; 100(5):437-42. PubMed ID: 25135378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
